The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Irritable Bowel Syndrome

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Irritable Bowel Syndrome


Psychiatry related information on Irritable Bowel Syndrome


High impact information on Irritable Bowel Syndrome


Chemical compound and disease context of Irritable Bowel Syndrome


Biological context of Irritable Bowel Syndrome


Anatomical context of Irritable Bowel Syndrome


Gene context of Irritable Bowel Syndrome


Analytical, diagnostic and therapeutic context of Irritable Bowel Syndrome


  1. Association of anxiety, neuroticism, and depression with dyspepsia of unknown cause. A case-control study. Talley, N.J., Fung, L.H., Gilligan, I.J., McNeil, D., Piper, D.W. Gastroenterology (1986) [Pubmed]
  2. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Delvaux, M., Louvel, D., Lagier, E., Scherrer, B., Abitbol, J.L., Frexinos, J. Gastroenterology (1999) [Pubmed]
  3. 5-hydroxytryptamine, ulcerative colitis, and irritable bowel syndrome: molecular connections. Galligan, J.J. Gastroenterology (2004) [Pubmed]
  4. Failure to define what constitutes a patient responder is a problem in the interpretation of the probiotic clinical trial evaluating the use of Bifidobacterium in irritable bowel syndrome. van Zanten, S.V. Gastroenterology (2005) [Pubmed]
  5. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Talley, N.J., McNeil, D., Hayden, A., Piper, D.W. Gastroenterology (1986) [Pubmed]
  6. Colonic myoelectrical activity in irritable-bowel syndrome. Effect of eating and anticholinergics. Sullivan, M.A., Cohen, S., Snape, W.J. N. Engl. J. Med. (1978) [Pubmed]
  7. Extra-intestinal manifestations associated with irritable bowel syndrome: a twin study. Svedberg, P., Johansson, S., Wallander, M.A., Hamelin, B., Pedersen, N.L. Aliment. Pharmacol. Ther. (2002) [Pubmed]
  8. Social learning, affective state and passive coping in irritable bowel syndrome and inflammatory bowel disease. Crane, C., Martin, M. General hospital psychiatry. (2004) [Pubmed]
  9. Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. Czimmer, J., Süto, G., Király, A., Mózsik, G. J. Physiol. Paris (2001) [Pubmed]
  10. Metabolism of vitamin A in inflammatory bowel disease. Janczewska, I., Bartnik, W., Butruk, E., Tomecki, R., Kazik, E., Ostrowski, J. Hepatogastroenterology (1991) [Pubmed]
  11. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Atkinson, W., Lockhart, S., Whorwell, P.J., Keevil, B., Houghton, L.A. Gastroenterology (2006) [Pubmed]
  12. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. O'Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O'Sullivan, G.C., Kiely, B., Collins, J.K., Shanahan, F., Quigley, E.M. Gastroenterology (2005) [Pubmed]
  13. Immune activation in irritable bowel syndrome: wrong title or wrong disease? Part 2. Poitras, P. Gastroenterology (2003) [Pubmed]
  14. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Berman, S.M., Chang, L., Suyenobu, B., Derbyshire, S.W., Stains, J., Fitzgerald, L., Mandelkern, M., Hamm, L., Vogt, B., Naliboff, B.D., Mayer, E.A. Gastroenterology (2002) [Pubmed]
  15. Celiac sprue as a possible cause of symptoms in presumed irritable bowel syndrome. Hasler, W.L. Gastroenterology (2002) [Pubmed]
  16. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Prather, C.M., Camilleri, M., Zinsmeister, A.R., McKinzie, S., Thomforde, G. Gastroenterology (2000) [Pubmed]
  17. Irritable-bowel syndrome with lactose intolerance. Ahmed, H.F. Lancet (1975) [Pubmed]
  18. Fructose malabsorption and the irritable bowel syndrome. Born, P., Vierling, T., Barina, W. Gastroenterology (1991) [Pubmed]
  19. Efficacy of oral disodium cromoglycate in patients with irritable bowel syndrome and positive skin prick tests to foods. Stefanini, G.F., Bazzocchi, G., Prati, E., Lanfranchi, G.A., Gasbarrini, G. Lancet (1986) [Pubmed]
  20. Airway responsiveness to inhaled methacholine in patients with irritable bowel syndrome. White, A.M., Stevens, W.H., Upton, A.R., O'Byrne, P.M., Collins, S.M. Gastroenterology (1991) [Pubmed]
  21. Electrochemical detector for breath hydrogen determination: measurement of small bowel transit time in normal subjects and patients with the irritable bowel syndrome. Corbett, C.L., Thomas, S., Read, N.W., Hobson, N., Bergman, I., Holdsworth, C.D. Gut (1981) [Pubmed]
  22. Does lactose maldigestion really play a role in the irritable bowel? Tolliver, B.A., Jackson, M.S., Jackson, K.L., Barnett, E.D., Chastang, J.F., DiPalma, J.A. J. Clin. Gastroenterol. (1996) [Pubmed]
  23. Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide. Narducci, F., Bassotti, G., Granata, M.T., Pelli, M.A., Gaburri, M., Palumbo, R., Morelli, A. Dig. Dis. Sci. (1986) [Pubmed]
  24. Sex differences of brain serotonin synthesis in patients with irritable bowel syndrome using alpha-[11C]methyl-L-tryptophan, positron emission tomography and statistical parametric mapping. Nakai, A., Kumakura, Y., Boivin, M., Rosa, P., Diksic, M., D'Souza, D., Kersey, K. Can. J. Gastroenterol. (2003) [Pubmed]
  25. 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Borman, R.A., Tilford, N.S., Harmer, D.W., Day, N., Ellis, E.S., Sheldrick, R.L., Carey, J., Coleman, R.A., Baxter, G.S. Br. J. Pharmacol. (2002) [Pubmed]
  26. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Lindqvist, S., Hernon, J., Sharp, P., Johns, N., Addison, S., Watson, M., Tighe, R., Greer, S., Mackay, J., Rhodes, M., Lewis, M., Stebbings, W., Speakman, C., Evangelista, S., Johnson, I., Williams, M. Br. J. Pharmacol. (2002) [Pubmed]
  27. Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome. Hasler, W.L., Schoenfeld, P. Drug safety : an international journal of medical toxicology and drug experience. (2004) [Pubmed]
  28. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Dunlop, S.P., Jenkins, D., Neal, K.R., Naesdal, J., Borgaonker, M., Collins, S.M., Spiller, R.C. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  29. Nifedipine reduces the colonic motor response to eating in patients with the irritable colon syndrome. Narducci, F., Bassotti, G., Gaburri, M., Farroni, F., Morelli, A. Am. J. Gastroenterol. (1985) [Pubmed]
  30. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Taché, Y., Martinez, V., Wang, L., Million, M. Br. J. Pharmacol. (2004) [Pubmed]
  31. Corticotropin-releasing factor and the brain-gut motor response to stress. Taché, Y., Martinez, V., Million, M., Rivier, J. Can. J. Gastroenterol. (1999) [Pubmed]
  32. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Simrén, M., Stotzer, P.O., Sjövall, H., Abrahamsson, H., Björnsson, E.S. European journal of gastroenterology & hepatology. (2003) [Pubmed]
  33. Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Lecci, A., Maggi, C.A. Expert Opin. Ther. Targets (2003) [Pubmed]
  34. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. van der Veek, P.P., van den Berg, M., de Kroon, Y.E., Verspaget, H.W., Masclee, A.A. Am. J. Gastroenterol. (2005) [Pubmed]
  35. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Whitehead, W.E., Bosmajian, L., Zonderman, A.B., Costa, P.T., Schuster, M.M. Gastroenterology (1988) [Pubmed]
  36. Lactase deficiency--a comparative study of diagnostic methods. Arvanitakis, C., Chen, G.H., Folscroft, J., Klotz, A.P. Am. J. Clin. Nutr. (1977) [Pubmed]
  37. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls. Kilkens, T.O., Honig, A., Fekkes, D., Brummer, R.J. Aliment. Pharmacol. Ther. (2005) [Pubmed]
  38. Review article: the safety profile of tegaserod. Schoenfeld, P. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  39. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Müller-Lissner, S., Holtmann, G., Rueegg, P., Weidinger, G., Löffler, H. Aliment. Pharmacol. Ther. (2005) [Pubmed]
WikiGenes - Universities